Vitamin D for Respiratory Health

Vitamin D and respiratory health is one of the clearest examples in nutrition of an effect that is real but confined to a subgroup. Across large individual-participant meta-analyses, supplementation reduces exacerbations of asthma and COPD — but almost entirely in people who were deficient at baseline, with little or no benefit in those already replete. That pattern is why headline trials in unselected populations often report nothing, and why the honest recommendation starts with a blood test rather than a bottle.

Dosing frequency also matters more than total dose. Daily or weekly moderate dosing is what produced benefit in the pooled analyses; large intermittent boluses did not, and have been associated with harm in other settings. For acute respiratory infections the picture is similar — modest protection concentrated in the deficient, not a general immune shield.

Respiratory epithelial cells express both the vitamin D receptor and CYP27B1, the enzyme that converts 25-hydroxyvitamin D into its active form, meaning the airway generates its own calcitriol locally from circulating substrate. When substrate is low, that local system cannot operate — the mechanistic reason baseline status determines response.

Locally produced calcitriol induces cathelicidin and beta-defensins, antimicrobial peptides that act directly against bacteria and enveloped viruses at the mucosal surface, and strengthens epithelial tight junctions against pathogen invasion. It simultaneously dampens the inflammatory arm of the response, shifting T-cell balance away from Th17 and towards regulatory phenotypes and reducing pro-inflammatory cytokine output. In airway disease this combination — better antimicrobial defence with less inflammatory overshoot — is what plausibly translates into fewer exacerbations. It also matters that daily dosing maintains steady substrate, whereas bolus dosing produces peaks and troughs plus a surge in catabolic 24-hydroxylase activity.

Daily moderate dosing, ideally guided by a 25(OH)D measurement, is the approach supported by the pooled data. Aim for sufficiency rather than a high level; there is no evidence that pushing levels above the normal range adds respiratory benefit.

The linked Thorax individual participant data meta-analysis examined vitamin D for preventing COPD exacerbations and found a reduction in moderate or severe exacerbation rate that was confined to participants with low baseline 25-hydroxyvitamin D; those with adequate levels saw no benefit. Individual participant data is the strongest design for detecting exactly this kind of subgroup effect, because it allows stratification that aggregate meta-analysis cannot. The linked updated systematic review and meta-analysis in The Lancet Respiratory Medicine assessed vitamin D for asthma exacerbations and refined earlier conclusions, again pointing to baseline status and dosing regimen as the determinants of effect rather than the intervention alone. Taken together these are high-quality analyses supporting a targeted rather than universal recommendation.

Vitamin D3 at maintenance doses is well tolerated and toxicity requires sustained intake far above normal supplementation. Excess presents as hypercalcaemia: nausea, thirst, confusion, and kidney stones with prolonged exposure.

Interactions divide into drugs that accelerate vitamin D breakdown and therefore raise requirement, and drugs whose risk increases if serum calcium rises.